| Name | Title | Contact Details |
|---|
Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.
BioStar Consulting, Inc. is a Greenbrier, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.
Iomai Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Omnichem USA is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.